Pulmatrix Valuation
| PULM Stock | USD 6.21 0.12 1.90% |
At this time, the company appears to be undervalued. Pulmatrix holds a recent Real Value of $7.9 per share. The prevailing price of the company is $6.21. Our model determines the value of Pulmatrix from analyzing the company fundamentals such as Current Valuation of 12.98 M, return on equity of -0.93, and Shares Owned By Insiders of 0.66 % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Pulmatrix's price fluctuation is slightly risky at this time. Calculation of the real value of Pulmatrix is based on 3 months time horizon. Increasing Pulmatrix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pulmatrix stock is determined by what a typical buyer is willing to pay for full or partial control of Pulmatrix. Since Pulmatrix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pulmatrix Stock. However, Pulmatrix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.21 | Real 7.9 | Hype 6.22 | Naive 6.96 |
The intrinsic value of Pulmatrix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pulmatrix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pulmatrix helps investors to forecast how Pulmatrix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pulmatrix more accurately as focusing exclusively on Pulmatrix's fundamentals will not take into account other important factors: Pulmatrix Total Value Analysis
Pulmatrix is at this time expected to have valuation of 12.98 M with market capitalization of 22.68 M, debt of 996 K, and cash on hands of 42.91 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Pulmatrix fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.98 M | 22.68 M | 996 K | 42.91 M |
Pulmatrix Investor Information
The book value of the company was at this time reported as 1.96. The company recorded a loss per share of 3.35. Pulmatrix last dividend was issued on the 6th of February 2019. The entity had 1:20 split on the 1st of March 2022. Based on the key measurements obtained from Pulmatrix's financial statements, Pulmatrix is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.Pulmatrix Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pulmatrix has an asset utilization ratio of 78.51 percent. This suggests that the Company is making $0.79 for each dollar of assets. An increasing asset utilization means that Pulmatrix is more efficient with each dollar of assets it utilizes for everyday operations.Pulmatrix Ownership Allocation
The market capitalization of Pulmatrix is $22.68 Million. Roughly 90.53 pct. of Pulmatrix outstanding shares are held by general public with 0.66 % owned by insiders and only 8.81 (%) by third-party entities. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Pulmatrix Profitability Analysis
The company reported the previous year's revenue of 7.81 M. Net Loss for the year was (9.56 M) with profit before overhead, payroll, taxes, and interest of 1.89 M.About Pulmatrix Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Pulmatrix. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Pulmatrix based exclusively on its fundamental and basic technical indicators. By analyzing Pulmatrix's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Pulmatrix's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pulmatrix. We calculate exposure to Pulmatrix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pulmatrix's related companies.Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.
Pulmatrix Growth Indicators
Investing in growth stocks can be very risky. If the company such as Pulmatrix does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 3.7 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.